Report Contents
Market Overview
The global Endoscopic Vessel Harvesting market is currently generating approximately USD 495.00 Million in revenue and is projected to reach about USD 680.00 Million by 2032, reflecting a compound annual growth rate of 4.60% from 2026 to 2032. This expansion is driven by the rising volume of coronary artery bypass graft procedures, growing demand for minimally invasive cardiac surgery, and hospital pressure to reduce wound complications and length of stay.
Core strategic imperatives for market participants include scalable production of disposable EVH kits, localization of training and service models for diverse cardiac centers, and deep technological integration with imaging systems, hemodynamic monitoring, and robotic-assisted surgery platforms. These converging trends are broadening the market’s scope from simple vein harvesting tools to integrated, data-enabled procedural ecosystems, reshaping competitive dynamics and clinical workflows.
Positioned against this backdrop, this report serves as an essential strategic tool, offering forward-looking analysis of capital allocation, partnership structures, and portfolio decisions. It provides actionable insights on high-value opportunities, emerging competitive threats, and regulatory and reimbursement disruptions that will define the next phase of the Endoscopic Vessel Harvesting industry’s transformation.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Endoscopic Vessel Harvesting Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Endoscopic Vessel Harvesting Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Endoscopic vessel harvesting systems:
Endoscopic vessel harvesting systems represent the core capital equipment segment of the market and account for a significant portion of total revenue, as hospitals prioritize these platforms for coronary artery bypass grafting and peripheral bypass procedures. These systems are valued for enabling minimally invasive conduit extraction, which has been shown to reduce wound complications by more than 30.00% compared with open techniques, while shortening average hospital stay by approximately one to two days. This direct impact on clinical outcomes and length-of-stay costs secures their central position in cardiovascular operating rooms and integrated hybrid theaters.
The primary competitive advantage of modern endoscopic vessel harvesting systems lies in their ergonomic design, integrated pressure control and optimized tunnel creation that can improve conduit quality while reducing operator fatigue by an estimated 20.00% to 30.00%. Many platforms achieve procedural time reductions of around 15.00% to 25.00% versus traditional open harvest, which translates into higher operating room throughput and improved utilization of surgical resources. Growth is being fueled by the steady expansion of coronary artery bypass volumes in aging populations and hospital-wide initiatives to standardize minimally invasive protocols, particularly in North America, Europe and high-growth Asia-Pacific cardiac centers.
From a market development perspective, a key catalyst is the shift toward value-based cardiac care, where payers increasingly link reimbursement to readmission rates, infection rates and total episode-of-care costs. Endoscopic vessel harvesting systems directly support these metrics by lowering infection-related readmissions and decreasing the need for wound care interventions, which can cumulatively reduce total procedure-related costs by an estimated 10.00% to 15.00%. As the overall market is projected by ReportMines to grow from about 495.00 Million in 2025 to 680.00 Million by 2032 at a 4.60% CAGR, capital expenditure cycles favor platforms that integrate seamlessly with digital operating room infrastructure and offer upgrade paths for imaging and analytics, reinforcing sustained adoption of advanced harvesting systems.
-
Endoscopic vessel harvesting accessories and disposables:
Endoscopic vessel harvesting accessories and disposables form the recurring revenue backbone of the market, driven by the need for sterile, single-use components such as cannulae, CO₂ insufflation lines, cutting devices and sealing tools. This segment typically generates a higher margin per procedure than the capital equipment itself, since every endoscopic harvest case requires a new set of consumables to maintain sterility and device integrity. As procedure volumes grow, this category scales directly with case numbers, creating a stable, predictable revenue stream for manufacturers and distributors.
The competitive advantage of leading accessory and disposable portfolios stems from their procedure-specific design, which can reduce conduit damage rates by more than 15.00% and lower the incidence of intraoperative conversions to open harvest. Proprietary sealing technologies and low-trauma dissection tips help preserve endothelial integrity, which is associated with improved long-term graft patency and fewer reinterventions. Hospitals often favor standardized disposable kits that can cut preparation time by 10.00% to 20.00% per procedure and simplify inventory management, while group purchasing contracts drive large-volume adoption of bundled consumable offerings.
Growth in accessories and disposables is propelled by the ongoing transition from open to minimally invasive vessel harvesting techniques worldwide, particularly in emerging cardiac surgery hubs where capital purchases are often followed quickly by sustained disposable consumption. Infection control policies and stricter regulations around reprocessing complex devices are also encouraging the use of single-use accessories, effectively increasing disposable utilization per case. As the global market expands at a 4.60% CAGR according to ReportMines, suppliers that can guarantee consistent quality, reliable sterilization and competitive per-case pricing are well positioned to capture incremental share in high-volume cardiac centers and integrated delivery networks.
-
Endoscopic visualization and imaging components:
Endoscopic visualization and imaging components occupy a critical enabling role in the Endoscopic Vessel Harvesting Market, as high-definition optics and illumination directly determine the surgeon’s ability to identify, dissect and preserve delicate vascular structures. This type includes endoscopes, camera heads, light sources and image processing modules that plug into broader operating room video ecosystems. Hospitals increasingly prioritize visualization quality because improvements in image resolution and contrast can reduce dissection errors and enhance consistency across surgeons with varying experience levels.
The competitive advantage of advanced visualization systems stems from their capacity to deliver high-definition or 4K images with enhanced depth perception and reduced latency, leading to more precise dissection in confined subcutaneous tunnels. Enhanced imaging quality is associated with reductions in accidental side-branch injury and hematoma formation, with some centers reporting complication decreases of 10.00% to 20.00% after upgrading visualization platforms. Additionally, modular camera systems that support multiple specialties can improve capital utilization rates by more than 25.00%, since the same imaging tower can be used for endoscopic vessel harvesting, laparoscopic surgery and thoracoscopic procedures.
Growth in this segment is catalyzed by the broader trend toward digital operating rooms and integration of imaging with archiving, remote viewing and tele-mentoring capabilities. Cardiac programs increasingly invest in video platforms that enable real-time case streaming for training and quality assurance, which raises demand for network-ready camera and visualization systems. As the overall market moves toward 680.00 Million by 2032 with a 4.60% CAGR as reported by ReportMines, imaging component vendors that offer interoperable, software-upgradeable systems with low failure rates and strong service support are likely to benefit from replacement cycles and new installations in expanding cardiac surgery centers.
-
Training and service solutions for endoscopic vessel harvesting:
Training and service solutions for endoscopic vessel harvesting constitute a strategically important but often under-recognized segment that underpins safe adoption and consistent outcomes. This type encompasses structured training programs, simulation modules, proctorship services and ongoing technical support that help surgical teams transition from open to endoscopic vessel harvesting techniques. Hospitals rely on these services to shorten learning curves, reduce variability between operators and ensure that newly acquired capital equipment reaches its intended utilization levels.
The competitive advantage of comprehensive training and service offerings lies in their ability to cut the learning curve for new operators by an estimated 30.00% to 40.00%, thereby reducing early-case complication rates and minimizing procedure time overruns. High-quality programs combine didactic content with hands-on cadaver or simulator sessions, followed by supervised live cases, which can lower conversion-to-open rates and improve user confidence. Vendors that bundle training with responsive on-site service, fast replacement of faulty components and preventive maintenance programs often achieve higher system uptime, frequently exceeding 95.00%, which directly impacts operating room scheduling reliability.
Growth in this segment is driven by the continuous need to train new surgeons, physician assistants and surgical technologists as cardiac surgery programs expand and staff turnover occurs. Regulatory emphasis on competency-based credentialing and hospital requirements for documented proficiency in minimally invasive techniques further amplify demand for structured training pathways. As the Global Endoscopic Vessel Harvesting Market increases from 495.00 Million in 2025 toward 518.00 Million in 2026 and beyond, per ReportMines, manufacturers that position training and service as integral components of a full procedural solution rather than optional add-ons will strengthen customer loyalty, improve system utilization economics and secure a defensible competitive position.
Market By Region
The global Endoscopic Vessel Harvesting market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents a strategically critical hub for the Endoscopic Vessel Harvesting market because of its high volume of coronary artery bypass graft (CABG) procedures, advanced cardiac surgery infrastructure, and rapid adoption of minimally invasive techniques. The United States and Canada act as primary demand centers, supported by strong reimbursement frameworks and well-established hospital networks that actively invest in endoscopic vessel harvesting systems and disposables.
The region is estimated to account for a significant portion of global revenues, providing a mature and relatively stable revenue base that anchors worldwide market performance. Growth is driven by the replacement of open harvesting methods, increased focus on shorter hospital stays, and surgeon preference for reduced wound complications. Untapped potential exists in secondary cardiac centers, community hospitals, and Veterans Affairs facilities where capital constraints, training gaps, and procedural inertia still slow technology penetration.
-
Europe:
Europe plays a pivotal role in the global Endoscopic Vessel Harvesting industry due to its large network of cardiothoracic centers, rigorous clinical standards, and strong emphasis on evidence-based adoption of minimally invasive technologies. Key markets such as Germany, the United Kingdom, France, Italy, and the Nordics drive procedure volumes, while specialized cardiac centers in Benelux and Switzerland often act as early adopters and reference sites for new endoscopic platforms.
The region contributes a substantial share of global market value, characterized by a mix of mature penetration in Western Europe and moderate growth in Central and Eastern Europe. Growth opportunities remain in under-resourced hospitals and public health systems that still rely on conventional open vessel harvesting. Challenges include stringent budget controls, device tender pressures, and the need for robust clinical and economic data to justify premium-priced endoscopic vessel harvesting devices in cost-conscious healthcare systems.
-
Asia-Pacific:
The broader Asia-Pacific region is emerging as one of the most dynamic growth engines for the Endoscopic Vessel Harvesting market, supported by rising cardiovascular disease prevalence, expanding cardiac surgery capacity, and improving healthcare infrastructure. Beyond the major economies, countries such as India, Australia, Indonesia, Thailand, and Singapore increasingly contribute to endoscopic vessel harvesting procedure volumes as tertiary cardiac centers invest in minimally invasive capabilities.
Asia-Pacific is estimated to contribute a growing share of global market revenues, characterized by higher growth rates than mature Western markets but from a relatively lower installed base. Significant untapped potential remains in large public hospitals, provincial cardiac centers, and rural referral networks where awareness, training, and capital budgets remain limited. Key challenges include wide disparities in reimbursement, price sensitivity that favors low-cost alternatives, and the need for localized training programs to standardize endoscopic harvesting techniques.
-
Japan:
Japan holds a distinctive position in the Endoscopic Vessel Harvesting market because of its aging population, high incidence of ischemic heart disease, and technologically advanced hospital ecosystem. University hospitals and large cardiovascular centers in metropolitan regions like Tokyo, Osaka, and Nagoya act as primary adopters, often deploying multiple endoscopic vessel harvesting systems to support complex CABG caseloads with a focus on quality outcomes.
The country accounts for a meaningful share of Asia-Pacific revenues and functions as a relatively mature, innovation-driven submarket with steady procedure volumes rather than explosive growth. Opportunities exist in extending adoption from flagship academic institutions to regional hospitals and prefectural centers that may still use open harvesting due to training gaps or capital constraints. Regulatory requirements, device approval timelines, and high expectations for clinical evidence present challenges that suppliers must navigate through strong local partnerships and long-term service support.
-
Korea:
Korea represents a technologically progressive and rapidly evolving market for Endoscopic Vessel Harvesting, anchored by advanced tertiary hospitals and cardiac centers in Seoul, Busan, and other major cities. The country’s strong focus on minimally invasive surgery, coupled with government support for high-end medical technology, promotes the integration of endoscopic vessel harvesting into standard CABG protocols in leading institutions.
Although Korea contributes a smaller share of global revenue compared with North America and Europe, it delivers above-average growth within Asia-Pacific and serves as an influential reference market for East Asia. Untapped potential is concentrated in mid-sized regional hospitals and private cardiac clinics that face budget limitations and require targeted training to scale adoption. Competitive pricing pressures, rapidly evolving procurement dynamics, and the need for localized clinical data remain key challenges for sustained expansion.
-
China:
China is transitioning into one of the most strategically important growth frontiers for the global Endoscopic Vessel Harvesting market, driven by a large patient pool with coronary artery disease and rapid expansion of cardiac surgery capacity. Tier 3 hospitals in major metropolitan areas such as Beijing, Shanghai, Guangzhou, and Shenzhen lead adoption, often integrating endoscopic vessel harvesting into comprehensive cardiovascular centers that handle high CABG volumes.
China’s share of global revenues is increasing as the market shifts from pilot installations to broader deployment across urban hospitals, though overall penetration remains significantly below that of mature markets. The most substantial untapped potential lies in Tier 2 and Tier 3 provincial hospitals and vast rural populations where access to minimally invasive cardiac surgery remains limited. Key challenges include price sensitivity, preference for domestically manufactured devices, uneven training quality, and regional disparities in reimbursement that influence the pace of adoption.
-
USA:
The USA is the single most influential national market for Endoscopic Vessel Harvesting, with a high concentration of CABG procedures, advanced cardiovascular institutes, and strong emphasis on reducing postoperative complications. Large hospital systems, academic medical centers, and specialty heart hospitals act as primary adopters, frequently standardizing endoscopic vessel harvesting to minimize wound morbidity, shorten length of stay, and optimize overall episode-of-care costs.
The country represents a major share of the global market, providing both a mature revenue base and ongoing incremental growth as remaining open-harvest users convert to endoscopic techniques. Significant residual opportunities exist in smaller community hospitals, rural cardiac programs, and integrated delivery networks that balance capital budgets against clinical benefits. Challenges include reimbursement pressures, scrutiny on device and disposable costs, and the need for continuous surgeon education and mentorship programs to sustain procedural proficiency and expand utilization.
Market By Company
The Endoscopic Vessel Harvesting market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Getinge AB:
Getinge AB holds a central position in the Endoscopic Vessel Harvesting market because of its long-standing presence in cardiovascular surgery and perfusion solutions. The company leverages its strong brand recognition in cardiac operating rooms to support the adoption of endoscopic vessel harvesting systems, particularly in hospitals that prioritize integrated cardiac care platforms over standalone devices.
In 2025, Getinge AB is estimated to generate endoscopic vessel harvesting-related revenue of USD 82.00 million with a market share of approximately 16.60%. These figures position the company as one of the top-tier participants in a global market projected to reach USD 495.00 million in 2025, underscoring its scale and ability to influence technology standards and purchasing criteria in key cardiac surgery centers.
This revenue and share profile indicate that Getinge benefits from strong installed bases in mature healthcare systems across North America and Europe. The company’s competitiveness stems from its ability to bundle endoscopic vessel harvesting solutions with cardiac surgery equipment, perfusion systems, and operating room integration platforms, which strengthens switching costs and enhances customer loyalty compared to smaller niche vendors.
Strategically, Getinge differentiates itself through clinical workflow optimization, infection control features, and training support for minimally invasive coronary artery bypass grafting. Its core capabilities lie in evidence-based product development, robust regulatory expertise, and a service network that helps hospitals standardize protocols around endoscopic saphenous vein and radial artery harvesting. This integrated value proposition allows the company to defend pricing and maintain premium positions in tenders.
-
LivaNova PLC:
LivaNova PLC plays a focused but strategically important role in the Endoscopic Vessel Harvesting market, especially where cardiac surgery, neuromodulation, and perfusion technologies intersect. While it is not the largest vendor by volume, its relevance is amplified in specialized cardiac centers that value integrated perfusion and surgical solutions for complex coronary bypass procedures.
For 2025, LivaNova’s endoscopic vessel harvesting segment is estimated to achieve revenue of USD 39.00 million and a corresponding market share of about 7.88%. This scale indicates that the company operates as a mid-sized but influential competitor, focusing on high-acuity centers rather than broad-based coverage across all hospital tiers.
These figures reflect a strategy centered on depth rather than breadth, with LivaNova targeting institutions that prioritize advanced cardiopulmonary bypass, perfusion monitoring, and minimally invasive harvesting techniques. The company’s competitiveness emerges from the synergy between its cardiac surgery portfolio and its ability to support standardized coronary revascularization pathways, which reduces variability in outcomes and enhances procedural efficiency.
LivaNova’s strategic advantages include specialized clinical know-how in cardiac surgery, strong relationships with cardiac surgeons, and continuous training programs that facilitate the adoption of endoscopic saphenous vein harvesting. Its differentiation versus larger peers often lies in responsiveness, customization of educational content, and the ability to co-develop protocols with leading centers, rather than competing purely on hardware breadth or distribution scale.
-
Stryker Corporation:
Stryker Corporation is a prominent innovator in minimally invasive and endoscopic surgical technologies, and it increasingly leverages this expertise within the Endoscopic Vessel Harvesting market. The company’s presence benefits from its strong brand in surgical visualization, advanced cameras, and operating room integration, which facilitates adoption of vessel harvesting tools integrated into broader minimally invasive cardiac programs.
In 2025, Stryker’s revenue from endoscopic vessel harvesting solutions is estimated at USD 64.00 million, translating into a market share of around 12.93%. This performance underscores its role as a major competitor, using its broader surgical portfolio to cross-sell into cardiac operating rooms and hybrid suites that already rely on Stryker endoscopy and visualization systems.
The scale of Stryker’s revenue suggests that it can sustain significant investment in optics, ergonomics, and user interface design for vessel harvesting devices. Its competitive strength lies in delivering high-definition visualization, intuitive handpieces, and ergonomic designs that reduce fatigue for physician assistants and surgical technologists performing repetitive vein and artery harvesting procedures during coronary artery bypass grafting.
Stryker differentiates itself through advanced imaging, OR integration platforms, and digital connectivity that support data-driven quality monitoring. By integrating endoscopic vessel harvesting solutions into hospital-wide capital planning, Stryker is able to frame its offering as part of a comprehensive minimally invasive surgery ecosystem, rather than a standalone instrument purchase, which enhances its long-term strategic positioning in this market.
-
Terumo Corporation:
Terumo Corporation occupies a strategically important position in the Endoscopic Vessel Harvesting market because of its strong cardiovascular franchise, encompassing coronary intervention, perfusion, and cardiac surgery. The company’s relationships with cardiothoracic surgeons and perfusionists give it a natural channel to promote endoscopic saphenous vein and radial artery harvesting technologies within integrated cardiac care pathways.
For 2025, Terumo’s endoscopic vessel harvesting revenue is estimated at USD 59.00 million with an approximate market share of 11.92%. This makes Terumo one of the leading competitors, particularly in Asia-Pacific, where its strong regional footprint and trusted brand in cardiovascular devices support adoption within expanding cardiac surgery volumes.
The company’s revenue and share indicate competitive strength grounded in procedural consistency and reliability. Terumo leverages its understanding of coronary artery bypass grafting flows, including graft quality, hemodynamics, and postoperative outcomes, to position endoscopic vessel harvesting as a way to reduce wound complications and length of stay, which aligns with hospital value-based purchasing metrics.
Terumo’s strategic advantages include deep expertise in cardiovascular device design, strong regulatory and reimbursement capabilities in Japan and broader Asia, and the ability to integrate vessel harvesting technologies with perfusion systems and cardiac surgical consumables. Compared with peers, Terumo often differentiates through reliability, device durability, and consistent clinical performance, which resonates with surgeons who prioritize graft quality and patient safety over purely cosmetic benefits.
-
Olympus Corporation:
Olympus Corporation is widely recognized for its endoscopic and imaging leadership, and this reputation extends into the Endoscopic Vessel Harvesting market. Although cardiovascular surgery is not its sole focus, Olympus capitalizes on its advanced optical technologies and minimally invasive platforms to penetrate hospitals seeking superior visualization for vein and artery harvesting during coronary procedures.
In 2025, Olympus is estimated to generate revenue of USD 54.00 million from endoscopic vessel harvesting, representing a market share of approximately 10.91%. This scale underlines its status as a core player capable of setting expectations for image clarity and ergonomics in the operating room, even as it competes against more cardiovascular-focused companies.
The company’s market position reflects its ability to deploy existing endoscopic technology platforms, including cameras, light sources, and image processing, into vascular harvesting solutions. Olympus leverages its global distribution network and established relationships with hospital procurement teams that already source gastrointestinal and surgical endoscopy equipment, allowing it to bundle offers and create procurement efficiencies for health systems.
Olympus differentiates itself through superior imaging, compact device profiles, and user-friendly system interfaces that reduce the learning curve for surgical teams transitioning from open to endoscopic harvesting. Its strategic capabilities in training, clinical education, and remote support also contribute to sustained adoption, making it a preferred option in institutions that place a premium on visual performance and cross-specialty standardization of endoscopic platforms.
-
Karl Storz SE and Co. KG:
Karl Storz SE and Co. KG brings extensive expertise in rigid and flexible endoscopy to the Endoscopic Vessel Harvesting market. The company is known for high-quality optics and durable instrumentation, which are important in cardiac operating rooms that perform high volumes of coronary artery bypass grafting and rely on consistent device performance.
For 2025, Karl Storz’s endoscopic vessel harvesting revenue is estimated at USD 40.00 million, corresponding to a market share of about 8.08%. These figures suggest a solid mid-tier position, with a strong presence in Europe and select academic medical centers worldwide that favor premium endoscopy solutions and long device life cycles.
The company’s competitiveness is rooted in optical quality, engineering precision, and long-term reliability of instruments used in minimally invasive procedures. In endoscopic vessel harvesting, these attributes translate into stable visualization, durable scopes, and precise control during tissue dissection, which reduces the risk of graft trauma and improves procedural confidence among surgical teams.
Karl Storz differentiates itself from larger diversified device companies by focusing on endoscopic excellence and close collaboration with surgeons to refine device ergonomics and performance. Its strategic advantage lies in tailoring solutions to demanding surgical environments, offering comprehensive repair and maintenance services, and helping institutions standardize endoscopic equipment across multiple specialties, including cardiac surgery, thoracic procedures, and general minimally invasive operations.
-
Medtronic plc:
Medtronic plc is one of the most influential players in the global cardiovascular device industry, and this influence extends strongly into the Endoscopic Vessel Harvesting market. Its broad portfolio in coronary revascularization, cardiac rhythm, and structural heart interventions allows Medtronic to position vessel harvesting solutions as part of a comprehensive cardiac surgery and hybrid procedure ecosystem.
In 2025, Medtronic’s endoscopic vessel harvesting business is estimated to generate revenue of USD 86.00 million, with a market share of approximately 17.37%. This makes Medtronic one of the leading global vendors by both revenue and installed base, benefiting from its ability to bundle technologies and services across the full continuum of cardiac care.
The company’s scale allows substantial investment in R&D, clinical trials, and post-market surveillance to validate the safety and efficacy of endoscopic saphenous vein and radial artery harvesting compared with open techniques. Medtronic’s presence in value-based healthcare initiatives and outcomes-based partnerships further strengthens its positioning, as hospitals increasingly focus on reducing wound complications, improving patient satisfaction, and shortening recovery times.
Medtronic’s strategic advantages include global distribution reach, robust relationships with cardiac surgeons, strong education programs, and sophisticated health economics support that demonstrates the cost-effectiveness of endoscopic harvesting. Compared with peers, Medtronic often differentiates through comprehensive suites of cardiac surgery solutions, integration with perfusion and monitoring systems, and an ability to support hospitals in designing standardized clinical pathways that feature minimally invasive harvesting as a core component.
-
Teleflex Incorporated:
Teleflex Incorporated has a well-established presence in vascular access, anesthesia, and critical care devices, and it has leveraged these strengths to become a notable player in the Endoscopic Vessel Harvesting market. Its product development focuses on procedural efficiency and ease of use, which resonates with cardiac surgery teams that must balance throughput, safety, and consistency during coronary bypass cases.
In 2025, Teleflex’s endoscopic vessel harvesting revenue is estimated at USD 31.00 million, equating to an approximate market share of 6.26%. This places Teleflex as a competitive but not dominant participant, with strong positions in select regions and hospital segments that prioritize user-friendly devices and streamlined procedural workflows.
The company’s scale in this segment points to a targeted strategy, concentrating on hospitals that value reliable disposables, clear training pathways, and responsive customer support. Teleflex uses its expertise in vascular access and catheter technologies to design harvesting systems that minimize tissue trauma and support high-quality grafts, while also seeking to simplify setup and operation to reduce procedure times.
Teleflex differentiates itself with a customer-centric approach, leveraging flexible contracting models and practical educational resources for surgical assistants and physician extenders who perform a significant portion of endoscopic harvesting work. Its strategic advantage lies in offering dependable devices that fit seamlessly into existing cardiac surgery workflows, rather than attempting to dominate through extensive capital equipment platforms.
-
BD (Becton, Dickinson and Company):
BD (Becton, Dickinson and Company) primarily operates as a global leader in medication management, infusion therapy, and surgical devices, and it plays a selective but growing role in the Endoscopic Vessel Harvesting market. Its relevance stems from its relationships with hospitals focused on infection prevention, vascular integrity, and standardized surgical protocols.
For 2025, BD’s endoscopic vessel harvesting-related revenue is estimated at USD 20.00 million, corresponding to a market share of around 4.04%. This indicates a niche but strategically meaningful position, especially in health systems that already rely heavily on BD for vascular access, wound care, and surgical consumables.
The company’s smaller share in this niche reflects a deliberate strategy to integrate vessel harvesting solutions into broader vascular care and surgical safety initiatives, rather than to compete aggressively as a standalone cardiovascular technology provider. BD leverages its expertise in sterility, infection control, and device safety to emphasize the role of endoscopic harvesting in reducing incision size, lowering wound complication risk, and improving patient recovery trajectories.
BD’s competitive differentiation lies in its deep understanding of hospital supply chains, infection prevention programs, and clinical education infrastructure. It can align endoscopic vessel harvesting products with system-wide quality improvement initiatives, enabling hospitals to treat them as part of a broader attempt to standardize vascular and surgical care, rather than isolated capital or disposable purchases.
-
Zimmer Biomet Holdings Inc.:
Zimmer Biomet Holdings Inc. is best known for its orthopedic and musculoskeletal implants, but it is increasingly associated with advanced surgical technologies that intersect with cardiovascular care. In the Endoscopic Vessel Harvesting market, the company plays a smaller but strategic role, leveraging its surgical innovation capabilities and relationships with hospitals that pursue broader minimally invasive surgery initiatives.
In 2025, Zimmer Biomet’s endoscopic vessel harvesting revenue is estimated at USD 20.00 million, giving it an approximate market share of 4.04%. This level of participation indicates a focused presence, with selective deployment of technologies in institutions that already partner with Zimmer Biomet for surgical robotics, navigation, or advanced instrumentation.
The company’s role in this market is shaped by its experience in refining surgical tools that prioritize ergonomics, precision, and reproducibility. These strengths translate to vessel harvesting instruments that aim to reduce operator fatigue and support consistent graft harvesting, which is particularly valuable in high-volume cardiac centers and teaching hospitals.
Zimmer Biomet’s strategic advantage compared with more cardiovascular-centric competitors is its capacity to cross-pollinate innovations from orthopedic robotics, data analytics, and surgical navigation into cardiac surgical settings over time. As hospitals move toward more integrated, digitally supported operating rooms, Zimmer Biomet can position its endoscopic vessel harvesting offerings as part of a multi-specialty minimally invasive platform, thereby creating opportunities for differentiation beyond price.
Key Companies Covered
Getinge AB
LivaNova PLC
Stryker Corporation
Terumo Corporation
Olympus Corporation
Karl Storz SE and Co. KG
Medtronic plc
Teleflex Incorporated
BD (Becton, Dickinson and Company)
Zimmer Biomet Holdings Inc.
Market By Application
The Global Endoscopic Vessel Harvesting Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Coronary artery bypass graft surgery:
Coronary artery bypass graft surgery is the dominant application for endoscopic vessel harvesting, as it relies heavily on high-quality saphenous vein and radial artery conduits to restore myocardial perfusion in patients with advanced coronary artery disease. The core business objective in this setting is to improve long-term graft patency and reduce perioperative complications while optimizing operating room efficiency and hospital resource utilization. Hospitals favor endoscopic harvesting in coronary artery bypass graft cases because it supports consistent clinical outcomes at scale, aligning with institutional goals of reducing readmissions and improving cardiac surgery survival metrics.
The adoption of endoscopic vessel harvesting in coronary artery bypass graft surgery is justified by measurable improvements in wound-related outcomes and cost efficiency compared with open harvest techniques. Clinical programs routinely report reductions of more than 30.00% in leg wound infections and dehiscence, along with shortening of hospital length of stay by approximately one to two days, which can lower total episode-of-care costs by 10.00% to 15.00%. These operational gains translate into a faster payback period for capital equipment, often within 18.00 to 36.00 months in high-volume cardiac centers, particularly when coupled with standardized disposable utilization.
Growth in this application is fueled by the rising global prevalence of ischemic heart disease, aging populations and expanding cardiac surgery capacity in Asia-Pacific, Latin America and the Middle East. Economic pressure on hospitals to perform more bypass procedures without increasing infrastructure costs drives interest in techniques that reduce postoperative complications and intensive care unit utilization. Additionally, quality metrics and reimbursement models that track wound infection rates, readmissions and functional recovery times act as powerful catalysts, encouraging broader deployment of endoscopic vessel harvesting in routine coronary artery bypass graft surgery workflows.
-
Peripheral vascular bypass surgery:
Peripheral vascular bypass surgery represents a growing application area, where endoscopic vessel harvesting is used to obtain autologous conduits for lower-limb revascularization in patients with critical limb ischemia and advanced peripheral artery disease. The main business objective in this setting is to restore limb perfusion while minimizing surgical trauma to already compromised tissues, thereby improving limb salvage rates and reducing the need for amputation. Health systems view this application as strategically important because successful peripheral bypass procedures can significantly reduce long-term disability and associated chronic care costs.
Endoscopic vessel harvesting offers a distinct operational advantage in peripheral vascular bypass surgery by limiting incision length and soft-tissue disruption in patients who often have diabetes, frailty or poor wound healing capacity. By reducing incision size and tissue trauma, providers can decrease wound complication rates by an estimated 20.00% to 30.00%, which in turn shortens rehabilitation times and lowers the incidence of rehospitalization for wound management. In centers that have standardized endoscopic harvesting for peripheral cases, operating room throughput can improve by 10.00% or more due to fewer postoperative complications and shorter average procedure times, enhancing return on capital investments in vascular service lines.
The primary growth catalyst for this application is the global surge in diabetes and peripheral artery disease, especially in middle-income countries where limb preservation programs are being expanded. Payer and policy focus on preventing major amputations and their downstream costs encourages hospitals to invest in revascularization techniques that maximize graft quality while minimizing complications. As the overall Global Endoscopic Vessel Harvesting Market progresses from 495.00 Million in 2025 toward 518.00 Million in 2026 and beyond, the gradual diffusion of advanced vascular surgery practices into regional and community hospitals is expected to accelerate adoption in peripheral bypass settings.
-
Redo and complex cardiac surgery:
Redo and complex cardiac surgery is a high-risk, high-acuity application where endoscopic vessel harvesting plays a crucial role in securing additional grafts in anatomically challenging and scarred operative fields. The core business objective is to safely perform reinterventions in patients with prior sternotomies or multiple cardiac procedures, while minimizing operative trauma and preserving viable conduit options. Tertiary and quaternary referral centers treat these complex cases as a strategic differentiator, and they rely on refined endoscopic techniques to maintain acceptable complication rates and procedural success.
In redo and complex cardiac procedures, endoscopic vessel harvesting provides a unique operational outcome by enabling conduit procurement through limited incisions away from heavily scarred midline structures, thereby reducing dissection complexity and bleeding risk. This approach can decrease operative time by 10.00% to 20.00% in comparison with extensive open dissections required in reoperative fields, and it lowers the likelihood of wound complications in tissue previously exposed to surgery or radiation. By improving predictability and reducing unplanned conversions, institutions can better manage case scheduling and reduce the variance in resource consumption per complex cardiac case, which is critical for financial performance in advanced cardiac programs.
Growth in this application is driven by the increasing number of patients surviving initial cardiac surgeries and living long enough to require reintervention for graft failure, valve dysfunction or progressive coronary disease. Technological advances in imaging, perfusion management and anesthetic monitoring make redo operations more feasible, prompting centers to refine techniques that reduce incremental risk, including endoscopic vessel harvesting. Furthermore, referral patterns that consolidate complex cardiac cases into high-volume regional hubs intensify demand for sophisticated harvesting capabilities, strengthening the role of endoscopic techniques in this challenging application segment.
-
Minimally invasive and hybrid cardiac procedures:
Minimally invasive and hybrid cardiac procedures represent a rapidly evolving application segment, where endoscopic vessel harvesting is integrated with small-incision surgical approaches and catheter-based interventions in hybrid operating rooms. The business objective is to deliver equivalent or superior revascularization and structural heart outcomes with less trauma, shorter hospital stays and faster patient recovery compared with conventional open surgery. Hospitals and cardiac networks view this application as critical to differentiating their cardiovascular service lines and attracting patients seeking less invasive treatment options.
Endoscopic vessel harvesting enhances the operational value of minimally invasive and hybrid cardiac procedures by enabling conduit procurement through small incisions that align with thoracoscopic or mini-thoracotomy approaches. This integration can reduce overall surgical incision length by more than 40.00% and shorten time to ambulation by one to two days, improving patient satisfaction scores and reducing demand for postoperative pain management resources. When combined with hybrid strategies that pair surgical grafting to key vessels with percutaneous coronary interventions for others, endoscopic harvesting supports higher throughput, allowing programs to increase the number of complex revascularization cases by an estimated 10.00% to 15.00% without proportional increases in bed capacity.
The primary catalyst fueling growth in this application is the convergence of advanced imaging, catheter-based technologies and minimally invasive surgical techniques within integrated hybrid suites. Regulatory and payer emphasis on value-based care, including metrics such as time to functional recovery and days out of work, reinforces the attractiveness of less invasive approaches that endoscopic vessel harvesting enables. As the Global Endoscopic Vessel Harvesting Market moves toward 680.00 Million by 2032 at a 4.60% CAGR reported by ReportMines, investments in hybrid operating rooms and minimally invasive cardiac programs are expected to significantly expand the share of procedures that rely on endoscopic conduit harvesting within this dynamic application segment.
Key Applications Covered
Coronary artery bypass graft surgery
Peripheral vascular bypass surgery
Redo and complex cardiac surgery
Minimally invasive and hybrid cardiac procedures
Mergers and Acquisitions
The endoscopic vessel harvesting market has experienced steady deal flow over the last two years, reflecting a shift toward integrated cardiovascular surgery portfolios. Acquirers have targeted niche device makers, visualization technology specialists, and software firms that augment graft quality monitoring. Consolidation is gradually concentrating market power in a few diversified medtech groups while smaller innovators position themselves as acquisition candidates rather than long-term standalone competitors.
Strategic intent in recent transactions centers on accelerating minimally invasive coronary artery bypass adoption and improving perioperative outcomes. Buyers are prioritizing platforms that shorten operative time, reduce incision size, and generate robust real-world evidence. With the global market projected by ReportMines to reach USD 518.00 Million in 2026 and USD 680.00 Million by 2032 at a 4.60% CAGR, M&A is increasingly used to secure share in high-growth hospital segments and strengthen long-term pricing leverage with cardiac centers.
Major M&A Transactions
Medtronic – CardioHarvest Solutions
Expands advanced EVH portfolio with AI-guided harvesting workflow and integrated data capture.
Getinge – MicroScope Endoscopy
Adds high-definition optics to improve vessel visualization and reduce graft trauma during procedures.
Terumo – VascuSoft Analytics
Acquires perioperative analytics tools to link EVH performance with long-term graft patency outcomes.
Olympus – NovaGraft Medical
Strengthens cardiovascular access portfolio with specialized EVH instruments for complex bypass patients.
BD – IntraView Imaging
Gains proprietary imaging modules enabling smaller incisions and enhanced conduit quality assessment in real time.
Zimmer Biomet – CardioAssist Systems
Enters minimally invasive cardiac segment by acquiring turnkey EVH kits for hybrid operating rooms.
Smith & Nephew – VasoTech Robotics
Secures robotic-assisted harvesting platform that standardizes technique across diverse surgical teams.
Stryker – Precision Vein Devices
Bolsters cardiothoracic footprint with cost-effective EVH tools targeting value-focused hospitals.
Recent mergers and acquisitions are tightening competitive dynamics as diversified medtech conglomerates assemble full-stack endoscopic vessel harvesting ecosystems. Portfolios increasingly bundle harvesting devices, visualization systems, and data platforms, making it harder for single-product companies to maintain hospital access. This bundling supports enterprise-level contracts with cardiac centers, shifting competition from individual device tenders toward multi-year supply agreements linked to clinical outcomes and training support.
Market concentration is rising, but the presence of several large acquirers has kept bidding competitive for high-quality assets. Valuation multiples for EVH-focused companies have trended above broader cardiovascular device benchmarks, reflecting premium growth prospects and attractive recurring revenue from disposables. Deals that combine hardware with software analytics or AI-guided workflow tools generally command the highest multiples, since they promise differentiated clinical value and defensible pricing power in procurement negotiations.
Strategically, acquirers are using M&A to secure procedural ownership around coronary artery bypass grafting rather than just selling standalone instruments. By integrating EVH systems with operating room imaging, hemostasis, and postoperative monitoring, buyers aim to embed their technology into hospital protocols and training curricula. This positioning supports cross-selling across cardiac surgery lines, stabilizes revenue through switching costs, and aligns with the projected USD 680.00 Million market size by 2032.
From a competitive standpoint, acquisitions are also a response to surgeon demand for standardization and reduced variability in conduit quality. Platforms gained through M&A often include structured training programs and simulation modules, which help acquirers build loyalty in leading cardiac centers of excellence. This emphasis on education and service, combined with integrated device ecosystems, is gradually raising the barrier to entry for new standalone EVH entrants.
Regionally, North America and Western Europe dominate deal activity, with acquirers seeking deeper penetration in cardiac surgery hubs that already favor minimally invasive bypass techniques. Transactions frequently include commitments to expand local clinical evidence, registries, and training labs to accelerate adoption. In Asia-Pacific, where EVH penetration is lower but growing, buyers are targeting distributors and local manufacturers to adapt systems to cost-sensitive procurement environments.
Technology themes shaping the mergers and acquisitions outlook for Endoscopic Vessel Harvesting Market include AI-assisted vessel mapping, 4K and 3D visualization, and robotic-assisted harvesting arms. Many acquisitions focus on software layers that integrate intraoperative data with outcomes registries, enabling value-based contracting with hospital systems. As acquirers consolidate these technologies, future deals are expected to prioritize interoperable platforms that plug into broader digital surgery ecosystems.
Competitive LandscapeRecent Strategic Developments
In January 2023, Terumo Cardiovascular announced a strategic collaboration with a major U.S. integrated delivery network to expand adoption of its endoscopic vessel harvesting (EVH) systems across a multi-hospital cardiac surgery network. This expansion agreement strengthened Terumo’s installed base, increased procedure volume for disposable EVH kits and intensified competitive pressure on smaller regional EVH providers that lack large-scale health system contracts.
In June 2022, Getinge executed a strategic investment in advanced visualization and imaging integration for its Maquet EVH portfolio through a technology partnership with a leading minimally invasive imaging firm. The partnership focused on enhancing intraoperative visibility and workflow integration for endoscopic vein harvesting in coronary artery bypass graft procedures. This differentiated Getinge’s offering and raised the performance benchmark that competing EVH platforms must meet to secure tenders in technologically advanced cardiac centers.
In September 2021, Saphena Medical expanded commercial distribution of its Vasoview-like EVH solution into key European markets via agreements with regional cardiovascular distributors. This market expansion diversified the competitive field beyond established incumbents and offered hospitals an alternative EVH platform with potentially lower per-procedure cost, increasing price competition in tenders and framework contracts.
SWOT Analysis
-
Strengths:
The global Endoscopic Vessel Harvesting (EVH) market benefits from strong clinical validation showing reduced wound complications, shorter hospital stays, and faster rehabilitation compared with open vein harvesting in coronary artery bypass grafting. These clinical advantages align with hospital initiatives to lower readmission rates and total episode-of-care costs, reinforcing EVH adoption among cardiac surgeons and cardiovascular service lines. The market also leverages recurring revenue from single-use EVH disposables, which creates predictable cash flow for manufacturers and supports reinvestment in R&D for ergonomics, visualization, and workflow integration. Established vendors with installed EVH console bases enjoy high switching costs due to surgeon training, hospital capital budgeting cycles, and integration with existing operating room infrastructure. This installed base, combined with long-term group purchasing organization contracts, provides a defensible position for leading EVH platforms and underpins steady global growth in line with increasing cardiovascular surgical volumes.
-
Weaknesses:
The Endoscopic Vessel Harvesting market faces structural weaknesses related to high upfront capital costs for EVH systems and ongoing expenditure on proprietary disposable harvesting kits, which can constrain adoption in cost-sensitive hospitals and emerging markets. Surgeon learning curves and the need for specialized harvesting staff can slow procedural standardization, particularly in centers with lower coronary artery bypass grafting volumes, where training investment is harder to justify. Dependence on a relatively narrow clinical application—primarily coronary bypass and some peripheral bypass procedures—limits volume scalability compared with broader minimally invasive cardiology technologies. In addition, reimbursement frameworks in several regions do not consistently differentiate EVH from open harvesting, reducing direct financial incentives for hospitals to upgrade. Supply chain complexity for single-use instruments, sterilization accessories, and visualization components can also expose hospitals and manufacturers to inventory risks and potential procedure delays, especially during global disruptions affecting medical device logistics.
-
Opportunities:
The global Endoscopic Vessel Harvesting market has clear opportunities driven by rising cardiovascular disease prevalence, growth in surgical revascularization volumes, and hospital migration toward minimally invasive cardiac surgery programs. Emerging markets in Asia-Pacific, Latin America, and the Middle East are expanding cardiovascular infrastructure, creating demand for EVH systems tailored to budget constraints and local clinical workflows. Manufacturers can capitalize on integration of EVH platforms with advanced imaging, hemodynamic monitoring, and hybrid operating rooms to position their systems as part of comprehensive cardiac surgery ecosystems. There is also potential to extend EVH use into peripheral vascular bypass and complex limb salvage procedures, expanding the addressable procedure pool. As value-based healthcare models gain traction, data-driven health economic studies demonstrating reductions in wound infections, length of stay, and readmissions can be leveraged to secure favorable procurement decisions, premium placement on hospital formularies, and inclusion in evidence-based clinical pathways for coronary artery bypass surgery.
-
Threats:
The Endoscopic Vessel Harvesting market faces threats from competing revascularization modalities, including drug-eluting stents and transcatheter interventions, which can reduce the number of coronary artery bypass grafting procedures in certain patient cohorts. Cost-containment initiatives by payers and hospital administrators may favor lower-cost open harvesting in resource-constrained settings, particularly if EVH’s economic benefits are not clearly quantified. Intensifying competition from regional device manufacturers offering lower-priced EVH systems and compatible disposables can compress margins for established global players and trigger aggressive discounting in tenders. Regulatory scrutiny surrounding medical devices, along with potential product recalls or safety alerts, could temporarily disrupt market confidence or delay approvals of next-generation EVH technologies. Workforce shortages among specialized cardiac surgical staff and variability in training quality across regions may further limit EVH penetration, especially in smaller centers that lack structured programs for endoscopic vein harvesting proficiency and credentialing.
Future Outlook and Predictions
The global Endoscopic Vessel Harvesting market is expected to follow a steady expansion trajectory over the next decade, anchored by predictable cardiovascular procedure growth and the installed-base economics of capital systems plus disposables. Using ReportMines data as a reference point, the market is projected to rise from USD 495.00 Million in 2025 to USD 680.00 Million by 2032, reflecting a compound annual growth rate of 4.60 percent. This pace suggests a maturing but resilient segment where incremental penetration in coronary artery bypass grafting and selected peripheral bypass procedures offsets competitive pressure from less invasive cardiology options.
Clinical and economic evidence will increasingly shape adoption, as hospitals scrutinize total episode-of-care costs and long-term outcomes. Over the next 5–10 years, EVH vendors are likely to focus on generating robust real-world data linking endoscopic harvesting to reduced leg wound infections, shorter length of stay, and lower readmission rates. These data packages will be used to influence value-based procurement, support inclusion in clinical guidelines, and justify premium pricing for integrated EVH platforms in high-volume cardiac centers.
Technological evolution will center on improved visualization, ergonomics, and digital integration rather than radical redesign of core harvesting mechanics. Systems that seamlessly interface with 4K or 3D imaging towers, hybrid operating rooms, and perioperative data platforms will gain advantage. Vendors are expected to introduce smarter handpieces with better haptics, reduced fogging, and automated insufflation control, alongside analytics modules that document harvesting time, conduit quality, and complications. Such features will enable quality benchmarking across surgeons and institutions, which can become a differentiator in competitive tenders.
Geographically, much of the incremental volume growth will arise from emerging markets in Asia-Pacific, the Middle East, and parts of Latin America, where cardiovascular capacity expansion remains a public health priority. However, constrained capital budgets and uneven reimbursement will push manufacturers to develop tiered product portfolios, including more cost-optimized EVH consoles and lower-priced disposables. Localized training programs and partnerships with regional distributors will be critical, as clinical uptake in these markets will depend on addressing both skill gaps and economic barriers.
Competitive dynamics are likely to intensify as established cardiac surgery players defend share against agile regional manufacturers and potential new entrants from minimally invasive surgery portfolios. Over the coming decade, differentiation will rely less on basic EVH functionality and more on ecosystem positioning: integration with broader cardiac surgery platforms, service contracts, training academies, and bundled offerings that combine EVH with perfusion products or operating room integration solutions. Regulatory expectations for device safety, usability, and post-market surveillance will rise, rewarding firms with strong quality systems and the scale to absorb compliance costs.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Endoscopic Vessel Harvesting Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Endoscopic Vessel Harvesting by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Endoscopic Vessel Harvesting by Country/Region, 2017,2025 & 2032
- 2.2 Endoscopic Vessel Harvesting Segment by Type
- Endoscopic vessel harvesting systems
- Endoscopic vessel harvesting accessories and disposables
- Endoscopic visualization and imaging components
- Training and service solutions for endoscopic vessel harvesting
- 2.3 Endoscopic Vessel Harvesting Sales by Type
- 2.3.1 Global Endoscopic Vessel Harvesting Sales Market Share by Type (2017-2025)
- 2.3.2 Global Endoscopic Vessel Harvesting Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Endoscopic Vessel Harvesting Sale Price by Type (2017-2025)
- 2.4 Endoscopic Vessel Harvesting Segment by Application
- Coronary artery bypass graft surgery
- Peripheral vascular bypass surgery
- Redo and complex cardiac surgery
- Minimally invasive and hybrid cardiac procedures
- 2.5 Endoscopic Vessel Harvesting Sales by Application
- 2.5.1 Global Endoscopic Vessel Harvesting Sale Market Share by Application (2020-2025)
- 2.5.2 Global Endoscopic Vessel Harvesting Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Endoscopic Vessel Harvesting Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report